Company: REVB
Filing Date: 2025-04-04
Form Type: DRS
Source: 0001213900-25-029022
Chunk: 98

Company: REVELATION BIOSCIENCES, INC.
Filing Date: 2025-04-04
Form: DRS
Chunk 98
---
, approximately half a million Americans sustain burn injuries requiring medical intervention. While most burn injuries do not require admission to a hospital, about 40,000 patients are admitted, with approximately 30,000 of them needing specialized treatment at a certified burn center (Norbury, 2016; American Burn Association, 2024). The total annual number of burn -relateddeaths is approximately 3,400, with invasive infection being the primary reason for death after the first 24 hours (Norbury, 2016). The overall mortality rate for severe burn patients is about 3.3%, but this increases to 20.6% in burn patients with cutaneous burn and inhalation injury, versus 10.5% for inhalation injury alone (American Burn Association, 2024). 60 Invasive infection including sepsis is the primary cause of death after burn injury, accounting for an estimated 51% of deaths. The most frequent clinical complications reported in patients admitted to a certified burn center were pneumonia (3.5%), cellulitis (3%), and urinary tract infection (2.6%). The frequency of pneumonia was greater in patients who had been injured by fire, and those with four or more days of mechanical ventilation (Norbury, 2016). Current Prevention, Treatment, and Detection Options Prevention and Treatment of AKI There are currently no therapeutics to prevent or treat AKI. Treatment for AKI requires hospitalization and intensive supportive care until kidney function recovers. In more serious cases, dialysis may be needed to help replace kidney function until kidneys can recover. The main treatment is to address what is causing the acute kidney injury. Prevention and Treatment of Chronic Kidney Disease In April 2021, The FDA approved the use of Farxiga (Dapagliflozin) to reduce the risk of kidney function decline, kidney failure, cardiovascular death and hospitalization for heart failure in adults who are at risk of disease progression. Farxiga was originally approved in 2014 for diabetic control in adults in addition to diet and exercise. In addition to the approved drug, other treatments include lifestyle changes to control health and weight, medications to control associated diseases such as high blood pressure or high cholesterol and for later stages, filtering the blood with a machine known as dialysis. Avoiding conditions or exposures that can harm the kidneys like certain medications or kidney infections is also beneficial. Still, at this time, there is a significant unmet need for therapies that slow disease progression and improve outcomes of patients